Systemic psoriasis therapy shows high between-country variation: A sign of unwarranted variation? Cross-sectional analysis of baseline data from the PSONET registries

British Journal of Dermatology

Volumn 169, Issue 3, 2013, Pages 710-714

  Garcia Doval, I ^a   Rustenbach, S J ^b   Stern, R ^c   Dam, T N ^d   Cohen, A D ^e   Baker, C ^f   Spuls, P I ^g   Naldi, L ^h  

^a Research Unit   (Spain)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c HARVARD MEDICAL SCHOOL   (United States)

^d ROSKILDE HOSPITAL   (Denmark)

^e BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g UNIVERSITY OF AMSTERDAM   (Netherlands)

^h FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

comparative effectiveness; drug therapy; epidemiology; psoriasis; psoriasis ; registries; research

Indexed keywords

CYCLOSPORIN A; FUMARIC ACID; INFLIXIMAB; METHOTREXATE; RETINOID;

AUSTRALIA; BIOLOGICAL THERAPY; CROSS-SECTIONAL STUDY; DENMARK; GERMANY; HUMAN; ISRAEL; ITALY; LETTER; NETHERLANDS; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; REGISTER; SPAIN; SYSTEMIC THERAPY;

*REGISTRIES; COMPARATIVE EFFECTIVENESS; EPIDEMIOLOGY; PSORIASIS; PSORIASIS/*DRUG THERAPY; RESEARCH;

AUSTRALIA; CROSS-SECTIONAL STUDIES; DELIVERY OF HEALTH CARE; EUROPE; HUMANS; PSORIASIS; REGISTRIES;

EID: 84883403500     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12344     Document Type: Letter

References (10)

1. Parisi R, Symmons DP, Griffiths CE, et al,. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133: 377-85.
2. Augustin M, Glaeske G, Schafer I, et al,. Processes of psoriasis health care in Germany-long-term analysis of data from the statutory health insurances. J Dtsch Dermatol Ges 2012; 10: 648-55.
3. Abuabara K, Wan J, Troxel AB, et al,. Variation in dermatologist beliefs about the safety and effectiveness of treatments for moderate to severe psoriasis. J Am Acad Dermatol 2013; 68: 262-9.
4. Wan J, Abuabara K, Troxel AB, et al,. Dermatologist preferences for first-line therapy of moderate to severe psoriasis in healthy adult patients. J Am Acad Dermatol 2012; 66: 376-86.
5. Pearce-Smith N,. Unwarranted variation: a reading list produced by QIPP Right Care. NHS Right Care Essential Reading, 2011. Available at: http://www.rightcare.nhs.uk/index.php/category/reading-list/ (last accessed 8 May 2013).
6. Wennberg JE,. Unwarranted variations in healthcare delivery: implications for academic medical centres. BMJ 2002; 325: 961-4.
7. PSONET. European surveillance network to monitor the long term effectiveness and safety of systemic agents in the treatment of psoriasis. Available at: http://www.psonet.eu. (last accessed 8 May 2013).
8. Garcia-Doval I, Carretero G, Vanaclocha F, et al,. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials. Arch Dermatol 2012; 148: 463-70.
9. Ormerod AD, Augustin M, Baker C, et al,. Challenges for synthesising data in a network of registries for systemic psoriasis therapies. Dermatology 2012; 224: 236-43.
10. Rivera R, Garcia-Doval I, Carretero G, et al,. BIOBADADERM, the Spanish Registry of Adverse Events Associated with Biologic Drugs in Dermatology: first report. Actas Dermosifiliogr 2011; 102: 132-41.